New hope for tough prostate cancers: adding carboplatin may slow disease
NCT ID NCT07591467
First seen May 17, 2026 · Last updated May 24, 2026 · Updated 1 time
Summary
This study tests whether adding the chemotherapy drug carboplatin to standard treatment can help men with a fast-growing type of prostate cancer that has spread. The cancer must have a BRCA gene mutation or show neuroendocrine features. About 330 men will receive either standard therapy alone or standard therapy plus carboplatin. The goal is to see if the combination delays cancer growth longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CLCC Paoli-Calmettes
Marseille, 13009, France
-
CLCC-ICL
Nancy, 54519, France
-
CLCC-Léon Bérard
Lyon, 69008, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hôpital Saint André
Bordeaux, 33075, France
Conditions
Explore the condition pages connected to this study.